Clinical Trials Browser

Phase 1/2 × surufatinib × 90 days × Clear all

NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Completed

Ovarian Neoplasms